{
  "ticker": "LLY",
  "timestamp": "2025-12-01T09:31:52.425483",
  "analysis_date": "2024-11-27",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "APPROVE",
  "final_position_pct": 0.05546,
  "final_position_dollars": 5546.01,
  "confidence": "MEDIUM",
  "reasoning": "The decision to approve a 5.55% position in Eli Lilly (LLY) is grounded in a favorable risk/reward scenario despite prevailing concerns. The stock's current valuation metrics, while high, present an opportunity for significant upside, especially in a recovering market. Additionally, the bullish sentiment from two evaluators reinforces the potential for growth, outweighing the bearish perspective.",
  "key_factors": [
    "Favorable risk/reward scenario",
    "Bullish sentiment from evaluators",
    "Potential for upside in a recovering market"
  ],
  "conditions": [
    "Market recovery",
    "Sustained earnings growth"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 831.9
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "BUY",
      "neutral": "SMALL BUY",
      "conservative": "AVOID"
    },
    "position_sizes": {
      "aggressive": 10.0,
      "neutral": 90.0,
      "conservative": 0
    },
    "agreements": [],
    "conflicts": [
      "Mixed views: 2 buy, 1 avoid"
    ],
    "avg_position_size": 0.3333333333333333,
    "red_flags": [
      {
        "flag": "Analysis failed",
        "severity": "HIGH",
        "source": "System"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 4.0,
    "range_max_pct": 6.5,
    "final_pct": 5.546,
    "final_dollars": 5546.01
  },
  "agent_votes": {
    "bullish": 2,
    "bearish": 1,
    "neutral": 1,
    "consensus": "LEAN_BULLISH"
  },
  "research_recommendation": "HOLD",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2024-11-27 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: APPROVE\n**Position:** 5.55% ($5,546.01)\n**Confidence:** MEDIUM\n\n## REASONING\nThe decision to approve a 5.55% position in Eli Lilly (LLY) is grounded in a favorable risk/reward scenario despite prevailing concerns. The stock's current valuation metrics, while high, present an opportunity for significant upside, especially in a recovering market. Additionally, the bullish sentiment from two evaluators reinforces the potential for growth, outweighing the bearish perspective.\n\n## KEY FACTORS\n\u2022 Favorable risk/reward scenario\n\u2022 Bullish sentiment from evaluators\n\u2022 Potential for upside in a recovering market\n\n## EVALUATOR SUMMARY\n- Aggressive: BUY @ 10%\n- Neutral: SMALL BUY @ 0.9%\n- Conservative: AVOID @ 0%\n\n## AGENT CONSENSUS\n- Bullish Votes: 2/4\n- Bearish Votes: 1/4\n- Neutral Votes: 1/4\n- Overall: Lean Bullish\n\n## POSITION SIZING\n- Range: 4.0% - 6.5%\n- Final: 5.55% ($5,546.01)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 Market recovery\n\u2022 Sustained earnings growth\n\n======================================================================\n"
}